sellModerate cluster of 2
Thomas Gad sold $396k of YMAB
CHIEF BUSINESS OFFICER at Y-mAbs Therapeutics, Inc.. 32,351 shares at an average of $12.23, traded May 21, 2024, filed May 23, 2024.
Warning score
44Value
$396k
32,351 shares
Holdings after
232,681
-12% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +16Trade size$396k at market
- +5Share of holdings soldSold 12% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-064808, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 21, 2024 | SOpen-market sale Common Stockindirect: By GAD Enterprises LLC | -25,000 | $12.00 | $300k | 240,032 | May 23, 2024 |
| May 23, 2024 | SOpen-market sale Common Stockindirect: By GAD Enterprises LLC | -7,351 | $13.00 | $96k | 232,681 | May 23, 2024 |
Related signals
Other insiders at Y-mAbs Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $57k 10,810 shares | -5% | |
| 60Notable | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $1.3M 95,000 shares | -58% | |
| 50Moderate | Y-mAbs Therapeutics, Inc. | Torben Lund-Hansen SVP & CHIEF TECHNICAL OFFICER | $769k 50,000 shares | -58% | |
| 41Moderate | Y-mAbs Therapeutics, Inc. | Joris Wilms SVP & CHIEF OPERATING OFFICER | $73k 5,000 shares | -14% | |
| 40Moderate | Y-mAbs Therapeutics, Inc. | Gerard Ber director | $8,664 722 shares | -31% | |
| 63Notable | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $841k 70,000 shares | -30% | |
| 53Moderate | Y-mAbs Therapeutics, Inc. | Bo Kruse EVP, CFO, SECRY & TREAS. | $723k 60,000 shares | -25% | |
| 38Weak | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $64k 3,900 shares | -2% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Vignesh Rajah SVP & CHIEF MEDICAL OFFICER | $28k 1,711 shares | -5% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Susan Laura Smith SVP & CHIEF COMMERCIAL OFFICER | $28k 1,682 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.